Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 5/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557496 | 0.81 | MCHR1 (0.44) | ALDH1A1CYP3A4TDP1MEN1KMT2A | |
| SCHEMBL557732 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPTKDM4EMEN1 | |
| SCHEMBL7575843 | 0.78 | MCHR1 (0.47) | ALDH1A1TDP1MAPTKDM4EMEN1 | |
| SCHEMBL10821313 | 0.78 | MAPK1 (0.44) | ALDH1A1CYP3A4TDP1MAPTKDM4E | |
| SCHEMBL558420 | 0.77 | PIK3CD (0.32) | — | |
| SCHEMBL558055 | 0.77 | F2RL3 (0.37) | MAPTKDM4E | |
| SCHEMBL7583364 | 0.77 | MCHR1 (0.48) | ALDH1A1TDP1MAPTKDM4EMEN1 | |
| SCHEMBL5542129 | 0.77 | L3MBTL1 (0.43) | ALDH1A1MAPTKDM4EMEN1GAA | |
| SCHEMBL558324 | 0.76 | ALDH1A1 (0.36) | ALDH1A1CYP3A4TDP1MAPTKDM4E | |
| SCHEMBL558547 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TDP1MAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| US-8507516-B2 | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493894-A1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2012020080-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-16 | — | — | WO | claimed |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | claimed |
| US-20060235210-A1 | Azo metal dyes and optical data carrier containing one such azo metal dye as a light absorbing compound in the information layer | LANXESS DEUTSCHLAND GMBH (DE) | 2006-10-19 | — | — | US | claimed |
| EP-1597321-A1 | AZO METAL DYES AND OPTICAL DATA CARRIER CONTAINING ONE SUCH AZO METAL DYE AS A LIGHT ABSORBING COMPOUND IN THE INFORMATION LAYER | LANXESS Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |
| WO-2004072185-A1 | AZO METAL DYES AND OPTICAL DATA CARRIER CONTAINING ONE SUCH AZO METAL DYE AS A LIGHT ABSORBING COMPOUND IN THE INFORMATION LAYER | LANXESS DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-0404440-B1 | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis, and related diseases | PFIZER (US) | 1997-11-05 | — | — | EP | claimed |
| US-5310888-A | Calcium detection | MILES INC. (US) | 1994-05-10 | — | — | US | claimed |
| EP-0404440-A2 | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis, and related diseases | PFIZER INC. (US) | 1990-12-27 | — | — | EP | claimed |
| US-4578469-A | COUMARIN DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-25 | — | — | US | claimed |
| US-4007188-A | DISPERSE DYES | SANDOZ LTD. (CH) | 1977-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | ALDH1A1 2305/4885CYP3A4 1562/4885TDP1 2107/4885 |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA6, CHRNA5 | ALDH1A1 1011/4885CYP3A4 2872/4885TDP1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.